26.2 USD
+0.93 (+3.68%)
We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year AMPH was profitable.
In the past year AMPH had a positive cash flow from operations.
In the past 5 years AMPH has always been profitable.
In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.70%, AMPH belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
AMPH has a better Return On Equity (14.37%) than 88.48% of its industry peers.
AMPH has a Return On Invested Capital of 8.51%. This is amongst the best in the industry. AMPH outperforms 86.91% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 12.85%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
Looking at the Profit Margin, with a value of 15.43%, AMPH belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
In the last couple of years the Profit Margin of AMPH has grown nicely.
AMPH has a better Operating Margin (20.73%) than 87.96% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
AMPH's Gross Margin of 49.36% is fine compared to the rest of the industry. AMPH outperforms 64.40% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
Compared to 1 year ago, AMPH has less shares outstanding
AMPH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AMPH has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.37 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.37, AMPH is in the better half of the industry, outperforming 62.83% of the companies in the same industry.
AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.49, AMPH belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
A Debt/Equity ratio of 0.78 indicates that AMPH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.78, AMPH is not doing good in the industry: 71.20% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.37 |
ROIC/WACC0.95
WACC8.97%
2.3 Liquidity
A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio of 3.12. This is comparable to the rest of the industry: AMPH outperforms 53.40% of its industry peers.
A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.21, AMPH is in line with its industry, outperforming 46.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
AMPH shows a decrease in Revenue. In the last year, the revenue decreased by -0.03%.
The Revenue has been growing by 17.82% on average over the past years. This is quite good.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
The Earnings Per Share is expected to grow by 0.14% on average over the next years.
Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 4.14% on average per year.
EPS Next Y-8.67%
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.62, which indicates a rather cheap valuation of AMPH.
93.72% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
AMPH's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.56.
A Price/Forward Earnings ratio of 6.97 indicates a rather cheap valuation of AMPH.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 93.72% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMPH to the average of the S&P500 Index (23.79), we can say AMPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.62 | ||
| Fwd PE | 6.97 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaper than 93.19% of the companies in the same industry.
90.05% of the companies in the same industry are more expensive than AMPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.85 | ||
| EV/EBITDA | 7.08 |
4.3 Compensation for Growth
The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:AMPH (12/15/2025, 11:24:57 AM)
26.2
+0.93 (+3.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners73.83%
Inst Owner Change0.4%
Ins Owners9.39%
Ins Owner Change0.06%
Market Cap1.20B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts80
Price Target32.64 (24.58%)
Short Float %10.32%
Short Ratio8.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-3.03%
PT rev (3m)-3.61%
EPS NQ rev (1m)5.33%
EPS NQ rev (3m)1.52%
EPS NY rev (1m)3.69%
EPS NY rev (3m)3.34%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.62 | ||
| Fwd PE | 6.97 | ||
| P/S | 1.66 | ||
| P/FCF | 10.85 | ||
| P/OCF | 7.91 | ||
| P/B | 1.55 | ||
| P/tB | 5.89 | ||
| EV/EBITDA | 7.08 |
EPS(TTM)3.44
EY13.13%
EPS(NY)3.76
Fwd EY14.35%
FCF(TTM)2.42
FCFY9.22%
OCF(TTM)3.31
OCFY12.65%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.12
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.37 |
F-Score5
WACC8.97%
ROIC/WACC0.95
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.67%
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.38%
EBIT Next 3Y0.74%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -8.67% in the next year.